著者
栗原 千絵子 松本 佳代子 石光 忠敬
出版者
公益社団法人 日本薬学会
雑誌
YAKUGAKU ZASSHI (ISSN:00316903)
巻号頁・発行日
vol.123, no.3, pp.91-106, 2003-03-01 (Released:2003-03-26)
参考文献数
102
被引用文献数
1 1

The Japanese Pharmaceutical Law was revised at the end of July 2002. The important features of this revision are the postmarketing safety scheme, especially for biological products, and reconstruction of the legislation for effective pharmaceutical development. This is based on the national policy to foster life sciences such as genetic research and regenerative medicine for both healthcare improvement and industrial promotion. Such research requires study participants who donate human tissue including abandoned embryos or aborted fetuses, which may touch the human dignity. In particular, fetal stem cell research appears to have unpredictable risks not only to women who undergo abortions but also to societal epistemology. The authors conducted risk-benefit assessment of fetal stem cell research, reviewing the scientific, ethical, legal, and social aspects, including a case study of critical appraisal on a report of the double-blind, sham surgery-controlled trial of implantation of fetal tissues in patients with Parkinson's disease conducted in the USA. It is concluded that risk-benefit assessment with a wide, profound perspective is necessary for advanced biotechnology. Some types of research should not be assessed based only on such utilitarian viewpoints as risk and benefit. Conscientious reflection is necessary to reach a public consensus on which types of human material can be utilized as research or pharmaceutical resources.

言及状況

外部データベース (DOI)

Twitter (3 users, 3 posts, 0 favorites)

色々あって今か・・・。 12週未満の妊娠中絶胎児の取り扱いについて https://t.co/TfHnabbXOo https://t.co/mfy7Doygwl 「改正薬事法は,(略)重い存在も含めて,人体 を「資源」として扱い,研究開発を進め,医薬品の 材料としていく」 12週。小さい。 https://t.co/8tyDDdHWiR
こういうの(十数年前)https://t.co/c07mqtb6vg

収集済み URL リスト